Related Experiment Video
Updated: Aug 15, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Identification of Novel Genes and Associated Drugs in Advanced Clear Cell Renal Cell Carcinoma by Bioinformatic
Meiqi Lu1, Liangxiang Xiao1, Bo Xu1
1Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University.
Abstract:
The current work screened differentially expressed genes (DEGs) related to advanced clear cell renal cell carcinoma (ccRCC) and found potential biomarkers and drugs for advanced ccRCC. After analyzing GSE53757 and GSE66271, we identified DEGs and performed the functional annotation, pathway enrichment, validation, survival analysis, and candidate drug analysis. We obtained 861 common DEGs from datasets between advanced ccRCC tissues and normal kidney tissues. Besides, we performed functional analysis under ontological conditions and carried out pathway analysis. The five most stable core gene groups and top 10 genes were screened using the Cytoscape software. We performed functional and pathway analyses again and found that the core genes were similar to total DEGs. After verification, the expression trends of the 10 hub genes did not change. Survival analysis showed high expressions of TOP2A, BIRC5, BUB1, MELK, RRM2, and TPX2 genes, suggesting that they might participate in cancer occurrence, migration, and relapse of ccRCC. The gene-drug analysis showed that gallium nitrate, cladribine, and amonafide were strongly associated with RRM2 and TOP2A. We found that RRM2 and TOP2A might be predictive biomarkers and novel targeted therapy for advanced ccRCC. These drugs (gallium nitrate, cladribine, and amonafide) might be used for treating advanced ccRCC.
Insights
Researchers identified key genes and potential drugs for advanced clear cell renal cell carcinoma (ccRCC). RRM2 and TOP2A show promise as biomarkers and therapeutic targets for ccRCC treatment.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Clear cell renal cell carcinoma (ccRCC) is a significant health concern, particularly in its advanced stages.
- Identifying novel biomarkers and therapeutic targets is crucial for improving ccRCC patient outcomes.
Purpose of the Study:
- To screen differentially expressed genes (DEGs) associated with advanced ccRCC.
- To identify potential diagnostic biomarkers and therapeutic drug candidates for advanced ccRCC.
Main Methods:
- Analysis of publicly available gene expression datasets (GSE53757, GSE66271) to identify common DEGs between advanced ccRCC and normal tissues.
- Functional annotation, pathway enrichment analysis, and survival analysis of identified DEGs.
- Utilized Cytoscape for screening core gene groups and hub genes, followed by validation and gene-drug association analysis.
Main Results:
- Identified 861 common DEGs in advanced ccRCC tissues.
- Screened 10 hub genes, with high expression of TOP2A, BIRC5, BUB1, MELK, RRM2, and TPX2 correlating with ccRCC progression.
- RRM2 and TOP2A were identified as potential predictive biomarkers, and gallium nitrate, cladribine, and amonafide as potential therapeutic agents.
Conclusions:
- RRM2 and TOP2A are implicated in the occurrence, migration, and relapse of ccRCC, suggesting their role as predictive biomarkers.
- Gallium nitrate, cladribine, and amonafide show potential as novel targeted therapies for advanced ccRCC.
- This study provides a foundation for developing new diagnostic and therapeutic strategies for advanced ccRCC.
